Back to search

Article

ct-DNA is useful to diagnose mutations at codon 641 of exon 16 of EZH2, which is a biomarker for relapse in patients with Diffuse Large B-cell Lymphoma treated with the R-CHOP scheme.

2022-02-04

Abstract excerpt

<h4>Background: </h4> The epigenetic regulator EZH2 is a subunit of the polycomb repressive complex 2 (PRC2), methylates H3K27, resulting in transcriptional silencing. The mutation at Y646 amino acid in the EZH2 gene is mutated in up to 40 % of B-cell lymphomas. We compared the presence of exon 16 EZH2 mutations in tumor samples and ctDNA in a prospective trial. The mutations were determined by sanger sequencing,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
30beb79a-ea3b-599c-9ba2-979cf98b5a3b
DOI
10.21203/rs.3.rs-1315493/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
ct-DNA is useful to diagnose mutations at codon 641 of exon 16 of EZH2, which is a biomarker for relapse in patients with Diffuse Large B-cell Lymphoma treated with the R-CHOP scheme.DOI 10.21203/rs.3.rs-1315493/v1
Mutations at Codon 641 of Exon 16 of EZH2 in Circulating Tumor DNA: A Biomarker for Relapse in Patients With Diffuse Large B-cell Lymphoma Treated With the R-CHOP Scheme.Semantic proximity
A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.Semantic proximity
Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?Semantic proximity
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.Semantic proximity
A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity
EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity
The PVT1, HULC, and HOTTIP expression changes due to treatment in Diffuse Large B-cell lymphomaSemantic proximity
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.Semantic proximity
Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of Diffuse Large B Cell LymphomaSemantic proximity
Molecular Karyotypes of Hodgkin and Reed–Sternberg Cells at Disease Onset Reveal Distinct Copy Number Alterations in Chemosensitive versus Refractory Hodgkin LymphomaSemantic proximity
Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.Semantic proximity
Select a neighboring publication to make it the new centre.